Efficacy of Montelukast on STEMl Patients

Exclusion Criteria

• •1. Cardiogenic shock, severe heart failure (Killip Class IV), or structural complications such as papillary muscle rupture;
• •2. Having received cardiopulmonary resuscitation ;
• •3. Severe and inadequately controlled hypertension (systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \> 110 mmHg);
• •4. Severe liver dysfunction (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) exceeding three times the upper limit of normal) or renal dysfunction (estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m²);
• •5. History of myocardial infarction;
• •6. Concomitant active bleeding or visceral hemorrhage;
• •7. Concomitant malignant tumors, lymphomas, leukemias, or other diseases with an expected survival time of less than 1 year;
• •8. Having undergone gastrointestinal surgery within the past 4 weeks that may affect the absorption of the investigational drug;
• •9. Pregnant or breastfeeding women;
• •10. Family history of psychiatric disorders;
• •11. Having been enrolled in another drug study within the past 4 weeks or currently receiving any investigational treatment other than the study drug;
• •12. Allergic to montelukast or having used montelukast within the past 4 weeks;
• •13. Unable to tolerate cardiac magnetic resonance imaging (e.g., patients with magnetic materials in the body or those with claustrophobia).